Cargando…

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase

Diminished Ikaros function has been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Therefore, a stringent regulation of Ikaros is of paramount importance for normal lymphocyte ontogeny. Here we provide genetic and biochemical evidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Hong, Qazi, Sanjive, Ozer, Zahide, Zhang, Jian, Ishkhanian, Rita, Uckun, Fatih M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747153/ https://www.ncbi.nlm.nih.gov/pubmed/23977012 http://dx.doi.org/10.1371/journal.pone.0071302

Ejemplares similares

Constitutive Function of the Ikaros Transcription Factor in Primary Leukemia Cells from Pediatric Newly Diagnosed High-Risk and Relapsed B-precursor ALL Patients
por: Uckun, Fatih M., et al.
Publicado: (2013)

ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma
por: Uckun, Fatih M., et al.
Publicado: (2022)

A Previously Unknown Unique Challenge for Inhibitors of SYK ATP-Binding Site: Role of SYK as A Cell Cycle Checkpoint Regulator()
por: Uckun, Fatih M., et al.
Publicado: (2014)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
por: Uckun, Fatih M., et al.
Publicado: (2022)

Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice()
por: Uckun, Fatih M., et al.
Publicado: (2015)

SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2014)

Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
por: Uckun, Fatih M., et al.
Publicado: (2018)

Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome
por: Qazi, Sanjive, et al.
Publicado: (2023)

Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes
por: Uckun, Fatih M., et al.
Publicado: (2023)

CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL
por: Qazi, Sanjive, et al.
Publicado: (2023)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma
por: Uckun, Fatih M., et al.
Publicado: (2023)

A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies
por: Uckun, Fatih M., et al.
Publicado: (2014)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-resistant B-precursor Acute Lymphoblastic Leukemia in Mice()
por: Uckun, Fatih M., et al.
Publicado: (2015)

Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma
por: Uckun, Fatih M., et al.
Publicado: (2018)

Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up
por: Uckun, Fatih M., et al.
Publicado: (2019)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair
por: Martin, Elodie, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance
por: Ng, Yen-Shing, et al.
Publicado: (2004)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
por: Weber, Alexander N. R., et al.
Publicado: (2017)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
por: Basile, Debora, et al.
Publicado: (2019)

Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
por: Wang, Qi, et al.
Publicado: (2019)

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hsfvuq2ea4kniae5a3b8fk94t3